14th Jan 2015 07:52
LONDON (Alliance News) - AstraZeneca PLC on Wednesday said the PEGASUS-TIMI 54 study has successfully met its primary efficacy targets, with a preliminary analysis showing no unexpected safety issues.
In the trial, which involved 21,000 patients, researchers assessed Brilinta tablets administered at either 60mg twice daily or 90mg twice daily, plus low-dose aspirin for the secondary prevention of atherothrombotic events in people who had suffered a heart attack one to three years prior to taking part in the study.
A preliminary analysis of the results from the study showed no unexpected safety issues, though AstraZeneca said full analysis of the data is ongoing.
Elisabeth Björk, vice president for Cardiovascular and Metabolic Diseases in Global Medicines Development at AstraZeneca, said the company was "very pleased with the top line results" of the study.
"The results build on existing understanding of the benefits of BRILINTA for patients with acute coronary syndrome and offer important clinical insights into its potential role for the longer term prevention of cardiovascular events," Björk added.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Astrazeneca